Dr. David LeBrun

Leader, Ontario Molecular Pathology Research Network

Dr. LeBrun’s research group studies perturbations in the regulation of gene transcription that underlie acute lymphoblastic leukemia (ALL). In particular, his group has been elucidating protein-protein interactions and patterns of genomic binding associated with the oncogenic transcription factor E2A-PBX1 (also called TCF3-PBX1). They also perform correlative research aimed at identifying prognostic and predictive biomarkers in malignant lymphoma, particularly follicular lymphoma and diffuse large B-cell lymphoma.

Current affiliations

  • Leader, Ontario Molecular Pathology Research Network
  • Principal Investigator, Queen’s Cancer Research Institute
  • Professor, Department of Pathology and Molecular Medicine, Queen’s University
  • Academic Director, Queen’s Laboratory for Molecular Pathology

Research interests

  • Acute lymphoblastic leukemia
  • Lymphoma
  • Gene transcription
  • E2A-PBX1
  • Chromatin
  • Genomics
  • Immunohistochemistry
  • Tissue microarrays
  • Multi-spectral immunofluorescence
  • Gene expression profiling

Select publications

See Dr. LeBrun’s recent publications on PubMed or on Google Scholar.

Previous experience and education

  • MD, Queen’s University
  • Residency, Anatomical Pathology, University of Toronto
  • Postdoctoral fellowship in molecular oncology, Stanford University

Opportunities to collaborate

LeBrun’s group is open to many types of collaboration. For example, they have assembled cohorts of cases of follicular lymphoma or diffuse large B-cell lymphoma from their institution. Pre-treatment FFPE biopsy samples are represented on tissue microarrays and baseline and outcome clinical data are available on all cases.

Visit OICR’s Collaborative Research Resources directory for more opportunities to collaborate with OICR researchers.

Related links

Queen’s Cancer Research Institute Faculty Page – Dr. David LeBrun


Dr. David LeBrun